- In order to promote the healthy development of my country’s peptide industry and strengthen exchanges and cooperation within the industry, on July 3-4, 2021, the second “China Peptide Industry Forum” hosted by the China Biochemical Pharmaceutical Industry Association was officially held in Ningbo, Zhejiang.
- The 2nd China Polypeptide Industry Forum received a warm response from related companies in the domestic polypeptide industry.
- In this forum, the participants conducted an in-depth analysis of the research directions and future development trends of the peptide industry at home and abroad.
In order to promote the healthy development of my country’s peptide industry and strengthen exchanges and cooperation within the industry, on July 3-4, 2021, the second “China Peptide Industry Forum” hosted by the China Biochemical Pharmaceutical Industry Association was officially held in Ningbo, Zhejiang.
The forum gathered researchers from companies involved in the research, development, production, and sales of peptide drugs, upstream and downstream related companies in the peptide industry, as well as researchers from universities and research institutes. The elites of all parties gathered together to seek the development of my country’s peptide industry. Chengdu Shengnuo Biopharmaceutical Co., Ltd. was invited to participate in this conference.
The 2nd China Polypeptide Industry Forum received a warm response from related companies in the domestic polypeptide industry.
More than 200 companies participated in the conference including Hainan Zhonghe Pharmaceutical Co., Ltd., Sinopeptide Biochemical Co., Ltd., and Novo Nordisk China R&D Center. Among them, more than 30 companies participating in the conference include: People’s National Peptide Group Co., Ltd., Gill Biochemical (Shanghai) Co., Ltd., Chengdu shengnuo biotechnologynology Co., Ltd., Shanghai Hequan Pharmaceutical Co., Ltd. and more than 30. A total of more than 500 experts, scholars, university representatives and business representatives attended this forum.
The conference focused on the frontier research, quality standards, production technology, clinical application and localization of the peptide industry, and explored the realization path and countermeasures to promote the high-end rise of strategic emerging industries, and create industry-supported, multi-disciplinary cross-integration, and close industry A conference that runs through the entire industry chain that integrates and links with the capital.
In this forum, the participants conducted an in-depth analysis of the research directions and future development trends of the peptide industry at home and abroad.
Huang Jian, technical director of shengnuo biotechnology, used a large amount of data to analyze the history and development status of the peptide industry in a keynote speech on “Peptide Application in the Big Health Industry”; Wen Yongjun, chairman of shengnuo biotechnology, explained the domestic synthetic peptide drugs The latest developments in foreign countries, and expressed his own views.
It is understood that, as an important member of China’s peptide industry, shengnuo biotechnology has been focusing on the pharmaceutical industry chain with peptides as its main business. The company’s main business is independent research and development, production, and sales. Strongly competitive peptide APIs and preparation products. At the same time, the company relies on its technological advantages in the field of peptide drug research and development and large-scale production to provide pharmaceutical companies at home and abroad with peptide innovative drug pharmaceutical research services, peptide product customized production services and peptide drugs Production technology transfer services.